Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3454015 | 0.99 | FYN (0.47) | FYNRXFP1ALDH1A1KDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL3454019 | 0.99 | FYN (0.47) | FYNRXFP1ALDH1A1KDM4EKMT2A | |
| SCHEMBL13110998 | 0.85 | FYN (0.53) | FYNMKNK1HSD17B10 | |
| Hydrochloric Acid SCHEMBL3454592 | 0.84 | FYN (0.52) | FYNMKNK1HSD17B10 | |
| Hydrochloric Acid SCHEMBL3454589 | 0.84 | FYN (0.52) | FYNMKNK1HSD17B10 | |
| SCHEMBL13110965 | 0.83 | FYN (0.53) | FYNMKNK1HSD17B10PGK1 | |
| Hydrochloric Acid SCHEMBL3453925 | 0.82 | FYN (0.52) | FYNMKNK1HSD17B10PGK1 | |
| Hydrochloric Acid SCHEMBL3453930 | 0.82 | FYN (0.52) | FYNMKNK1HSD17B10PGK1 | |
| SCHEMBL3454005 | 0.81 | FYN (0.50) | FYNALDH1A1KDM4EKMT2ANPC1 | |
| SCHEMBL3454008 | 0.81 | FYN (0.50) | FYNALDH1A1KDM4EKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820670-B2 | 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions | ALCON RESEARCH, LTD. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820670-B2 | 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions | ALCON RESEARCH, LTD. (US) | 2010-10-26 | — | — | US | disclosed |
| WO-2008079880-A1 | 6-AMINOIMIDAZO[1,2-B]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | ALCON RESEARCH, LTD. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153813-A1 | 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON MANUFACTURING, LTD. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153813-A1 | 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON MANUFACTURING, LTD. (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153813-A1 | 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOT2 | FYN 856/4885RXFP1 591/4885ALDH1A1 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.